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Dear Editor,  
 
Now is an extraordinarily exciting time for the multidisciplinary field of molecular 
radionuclide therapy (MRT) [1-3]. More patients than ever before are being treated 
with radiolabelled compounds and an increasing number of pharmaceutical 
companies incorporate radiopharmaceuticals into their portfolios.  
 
MRT allows specific irradiation of localised and disseminated disease with potentially 
fewer side effects than external beam radiotherapy (EBRT). However, aside from 
obvious improvements in radiochemistry, radiopharmacy, and dosimetry of MRT 
agents, a better understanding of the radiobiology, i.e. of the biological effects of 
ionising radiation of MRT agents, is needed.  
 
Radiobiology has been key in establishing optimal treatment regimens for EBRT 
whilst protecting healthy tissues. The paradigm of radiobiology is that tumour 
control probability and side effects are proportional to absorbed radiation dose; 
radiobiology is thus deeply connected with dosimetry. However, breakthroughs in 
EBRT effectiveness also required the understanding of concepts that purely fall 
under radiobiology.  
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Radiobiology of MRT is necessary to devise an optimised approach of use with 
regards to activity, therapy interval, vector, radionuclide, combinations, patient 
selection etc. The frequent ambiguity in predicting treatment outcome and 
inflexibility in altering set treatment regimens could lead to disease recurrence and 
avoidable treatment-related side effects that decrease quality of life. For example, it 
is becoming increasingly clear that some patients are being overtreated (resulting in 
high levels of toxicity), while some may be under-treated (no tumour regression) [1, 
3]. For example, in the NETTER I trial, although most of the patients showed stable 
disease, very few complete responses were observed [1]. Delivering a radiation dose 
high enough is necessary. However just this dose parameter might not always be 
sufficient to best predict treatment efficacy and toxicity [4]. More specifically, a 
multiparametric approach has to be considered to propose personalized treatments 
[5].  
 
It is now understood that extrapolation of radiobiology of EBRT to MRT is not 
straightforward, not only because of differences in dose-rate effects, which would 
give cells more time to repair lesions, but also because of activation of different 
molecular and cellular signalling pathways inducing different biological responses 
[6]. As an MRT radiobiological community, we therefore propose to further deepen 
our understanding for each therapeutic radiopharmaceutical of the following topics: 
 
Topic 1: Investigate the consequences of physical parameters on the tumour and 
normal tissue response. This includes the role of absorbed radiation dose 
assessment as a pre-requisite for establishing tumour control and normal tissue 
complication probability dose-effect curves, just as they exist for EBRT. Dose 
assessment on the tissue and (sub)cellular scale is essential for determining the role 
of dose-rate, dose fractionation, and dose distribution [7]. This challenge covers a 
hugely valuable field, which requires optimisation and standardisation, especially in 
light of the recent EU directive (European council directive 2013/59 Euratom [7-8]).  
 
Topic 2: Determine the role of radiopharmaceutical and target distribution both at 
the subcellular and tissue level. This includes determining target expression using 
imaging, (micro) autoradiography, and other techniques, which is a prerequisite for 
estimating radiotherapy efficacy and toxicity. Non-uniformity of the absorbed dose 
may lead to increased damage within these subcompartments leading to organ 
failure. Tissue and subcellular distribution of the radiopharmaceuticals also impacts 
the choice of the vector (e.g. internalising or not), as well as the subcellular target 
(e.g. nucleus, cell membrane, mitochondria etc.) and radionuclide (e.g. short or long 
particle/electron range, high or low LET).  
 
Topic 3: Determine the role of the tumour microenvironment and systemic 
reactions during MRT. As for EBRT, bystander effects and systemic effects involving 
the immune system (both innate and acquired) may contribute to MRT 
effectiveness. Bystander effects include intercellular communication between 
targeted tumour cells (including cancer stem cells) and neighbouring cells including 
other tumour cells, cancer associated fibroblasts, and endothelial cells [9]. Those 
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effects will lead to modifications in extracellular matrix structure, in perfusion with 
consequences on vector distribution and oxygen levels. 
 
Topic 4: Identify biomarkers of therapy response. Every patient is unique and 
tumour characteristics will vary between patients, but also between different 
metastatic sites within one patient. Currently, every patient receives the same MRT 
regimen based on their cancer type. To optimize treatment outcome, biomarkers 
should be identified. These can be simple markers such as target level expression or 
proliferation, or can be more specific markers such as anomalies in cellular pathways 
changing radiosensitivity of the tumour or healthy tissues (e.g. DNA damage repair 
defects). 
 
Topic 5: Determine optimal combination therapies, in particular, combinations of 
MRT with chemotherapy, immunotherapy, hormone therapy, or radiosensitizers. 
Combination of EBRT with a variety of these agents is common practice, and several 
recent (preclinical) studies have shown that MRT effects can be similarly amplified 
[10].  
 
Topic 6: Determine effects of MRT on healthy tissues, both in the short- and long-
term. Radiopharmaceuticals accumulate not only in tumour cells, but also in healthy 
tissues via normal physiological excretion routes and/or receptor expression on 
healthy cells. For example, the majority of radiopharmaceuticals are cleared from 
the body by the kidneys, and radiolabelled PSMA-targeting agents accumulate not 
only in prostate cancer cells but also in salivary and lacrimal glands. 
 
Our plan of action 
We think that a better understanding of the radiobiology of MRT is needed to 
optimise existing and new MRT strategies to their maximal clinical potential, 
efficacious in tumour cure whilst simultaneously safe for normal organs. While this 
includes optimisation of target and vector choice, radiochemistry and dosimetry 
physics, we aim to expand the field of radiobiology of MRT and form a large 
collaborative group to ensure clinical impact sooner rather than later. Now is the 
time to set up national initiatives and create a solid network that connects these at 
an international level. Hence, this call to arms.  
 
So, calling all researchers in radiobiology and MRT, if you are interested in helping to 
establish a tight community with the aim to increase the input of radiobiology in 
existing and new MRT, we propose you to join our working group 
(www.mrtradiobiology.com), which will foster radiobiology-oriented research in 
MRT by launching new funded research programs, organizing symposia together 
with education training.  
 
Partners for whom this would be interesting include radiobiologists, medical 
physicists, radiochemists, radiopharmacists, nuclear medicine clinicians, radiation 
oncologists, technologists, referring clinicians, radiation protection advisors, 
radioactive waste advisors, societies (EANM, ERRS), industry partners, and funding 
bodies where radiobiology is highlighted as a priority research area. 
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To conclude, let us invest time, effort and money into this very essential area of 
nuclear medicine research together.  
 
Acknowledgements. Authors would like to acknowledge Mark Konijnenberg, 
Emmanuel Deshayes, and Fijs van Leeuwen for their comments whilst preparing this 
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